Remus Pharmaceuticals (NSE:REMUS) EV-to-FCF : 315.95 (As of Apr. 08, 2025)

Remus Pharmaceuticals EV-to-FCF Chart

Competitive Comparison of Remus Pharmaceuticals's EV-to-FCF

For the Medical Distribution subindustry, Remus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Remus Pharmaceuticals's EV-to-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's EV-to-FCF falls into.

Remus Pharmaceuticals EV-to-FCF Calculation

Remus Pharmaceuticals's EV-to-FCF for today is calculated as:

Remus Pharmaceuticals's current Enterprise Value is ₹11,755 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was ₹37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals  (NSE:REMUS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Remus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

Remus Pharmaceuticals's share price for today is ₹1999.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹51.402.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Remus Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Remus Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Remus Pharmaceuticals Business Description